

Healthcare Common Procedure Coding System Quarterly Update

Effective April 1, 2022

The Centers for Medicare and Medicaid Services publishes updates to the Healthcare Procedure Coding System (HCPCS) on a quarterly basis. Public use files may be downloaded from the [“HCPCS Quarterly Update”](#) page.

Proprietary Lab Analyses (PLA)

0306U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future comparisons to evaluate for MRD
0307U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient, specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD
0313U	Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (i.e., negative, low probability of neoplasia or positive, high probability of neoplasia)
0314U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (i.e., benign, intermediate, malignant)
0315U	Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (i.e., Class 1, Class 2A, Class 2B)
0317U	Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm-generated evaluation reported as decreased or increased risk for lung cancer

Drugs

New HCPCS Codes

J9071 Injection, cyclophosphamide (auromedics), 5 mg
J9273 Injection, tisotumab vedotin-tftv, 1 mg
J9359 Injection, loncastuximab tesirine-lpyl, 0.075 mg

Pass-through Status Change

J0248 Remdesivir, 1 mg
J9304 Injection, pemetrexed (pemfexy), 10 mg

Discontinued HCPCS codes

C9087 Injection, cyclophosphamide (auromedics), 5 mg
C9084 Injection, loncastuximab tesirine-lpyl, 0.075 mg